Home » Stocks » Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc. (ARQT)

Stock Price: $27.62 USD -1.32 (-4.56%)
Updated Jul 16, 2020 12:33 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 1.05B
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 38.15M
EPS (ttm) -10.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 16, 2020
Last Price $27.62
Previous Close $28.94
Change ($) -1.32
Change (%) -4.56%
Day's Open 28.99
Day's Range 27.62 - 29.53
Day's Volume 24,907
52-Week Range 17.10 - 40.88

More Stats

Market Cap 1.05B
Enterprise Value 804.78M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 38.15M
Float 16.50M
EPS (basic) n/a
EPS (diluted) -10.27
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.66M
Short Ratio 14.05
Short % of Float 9.25%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 4.35
Revenue n/a
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 249.06M
Net Cash / Share 6.53
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -34.10%
ROE -43.67%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 3
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$43.25*
(56.59% upside)
Low
30.0
Current: 27.62
High
55.0
Target: 43.25
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017
Revenue---
Operating Income-43.13-19.74-4.11
Net Income-42.00-19.26-4.98
Shares Outstanding1.841.240.70
Earnings Per Share-22.78-15.53-7.16
Operating Cash Flow-42.84-14.09-3.78
Capital Expenditures-0.30--
Free Cash Flow-43.13-14.09-3.78
Cash & Equivalents10150.943.42
Total Debt0.31--
Net Cash / Debt10150.943.42
Assets10751.103.82
Liabilities5.552.831.66
Book Value-65.03-23.99-4.99
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Arcutis Biotherapeutics, Inc.
Country United States
Employees 43
CEO Todd Franklin Watanabe

Stock Information

Ticker Symbol ARQT
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ARQT

Description

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical cream formulation of roflumilast that is in Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of ARQ-151 for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory dermatoses; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin to the postulated site of inflammation in alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was founded in 2016 and is headquartered in Westlake Village, California.